Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy

STUDY OBJECTIVES: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the United States and European Union to treat excessive daytime sleepiness in patients with obstructive sleep apnea (OSA) (37.5–150 mg/day) and narcolepsy (75–150 mg/day). This analysis evaluated solriamfeto...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Sleep Med
Hlavní autoři: Schweitzer, Paula K., Strohl, Kingman P., Mayer, Geert, Rosenberg, Russell, Chandler, Patricia, Baladi, Michelle, Lee, Lawrence, Malhotra, Atul
Médium: Artigo
Jazyk:Inglês
Vydáno: American Academy of Sleep Medicine 2021
Témata:
Scientific Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8020710/
https://ncbi.nlm.nih.gov/pubmed/33179591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5664/jcsm.8992
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky